Introduction
============

Thyroiditis includes a complex spectrum of pathologies in which inflammatory and autoimmune processes may be detected in coexistence with benign and malignant proliferative lesions \[[@B1]\].

Therefore total thyroidectomy is increasingly being considered as the treatment of choice,

preventing the risk of reoperation required for possible recurrences. The present study reports the expression of inflammatory and proliferative biological markers in non-lesional healthy thyroid tissue obtained from patients undergoing total thyroidectomy for various thyroid diseases. Our study tried to rationalise the usefulness of total thyroidectomy in the management of thyroiditis hypothesizing that in a chronic thyroid disease the associated inflammatory and/or autoimmune phenomenona may involve the whole gland and exert a modulatory effect with respect to carcinogenesis \[[@B2]\]. The IL-6 pro-inflammatory cytokine IL-6Rb gp130 component mediates high affinity binding of IL-6 to the IL-6Ra subunit, and constitutes the functional component of other IL-6 cytokine family members receptor complexes, such as Oncostatin M, Leukemia Inhibitory Factor and IL-11, through a wide array of inflammatory and immune responses \[[@B3]\]. Cytokine-dependent signalling activation involves the STAT proteins family as an important pathway to modulate different cell functions, where STAT3 plays a central role in transmitting signals from the membrane to the nucleus \[[@B4]\]. The tumour suppressor p53 senses multiplicity of cellular stresses, gets activated by post-translational mechanisms to induce cell-cycle arrest, senescence, or apoptosis and is a STAT3 functional regulator \[[@B5]\]. Constitutively active STAT3 is frequently expressed in a variety of human cancers and transformed cell lines associated to a mutated inactive p53 \[[@B6],[@B7]\]. Thus, in this study, together with gp130, we analysed by immunohistochemistry the expression and intracellular localization of STAT3 and p53, to verify whether we could detect a cytoplasmic localization of the oncosuppressor protein indicative of its functional inactivation \[[@B8]\]. CK 19 cytokeratin which is expressed on epithelial tissue both in benign and malignant processes \[[@B9]\] was used as marker of epithelial tissue.

Patients and Methods
====================

Nineteen consecutive female patients who underwent total thyroidectomy for various thyroid diseases were investigated. Diseases included multinodular goiter (n = 10), follicular adenoma (n = 2), papillary carcinoma (n = 6) and Basedow disease \[[@B1]\]. Two patients with papillary carcinomas presented with concomitant Hashimoto disease or thyrotoxic goiter (Table [1](#T1){ref-type="table"}). Mean age of the patients was 44 years (range 19-59) and disease duration ranged from 6 months to 25 years. Anti-thyroid antibodies were negative in all the patients.

###### 

Results of the immunohistochemical staining on non-lesional tissue from 19 totally thyroidectomized patients.

  **Patient n**.   Disease                                STAT3   P53   CK19   Gp130
  ---------------- -------------------------------------- ------- ----- ------ -------
  1                Multinodular goiter                    N/C     N/C   neg    F
                                                                               
  2                Papillary cancer                       C       N/C   F      F
                                                                               
  3                Follicular adenoma                     N/C     N     ND     ND
                                                                               
  4                Multinodular goiter                    C       C     neg    Z
                                                                               
  5                Multinodular goiter                    C       C     neg    Z
                                                                               
  6                Papillary cancer                       N/C     C     Z      Z
                                                                               
  7                Multinodular goiter                    N/C     N/C   neg    Z
                                                                               
  8                Multinodular goiter                    neg     neg   neg    ND
                                                                               
  9                Multinodular goiter                    C       C     neg    F
                                                                               
  10               Papillary cancer & Thyrotoxic goiter   N/C     C     F      F
                                                                               
  11               Basedow disease                        C       C     F      F
                                                                               
  12               Papillary cancer                       N/C     N/C   Z      Z
                                                                               
  13               Multinodular goiter                    N/C     N     neg    Z
                                                                               
  14               Papillary c.                           neg     C     Z      Z
                                                                               
  15               Multinodular goiter                    N/C     N/C   F      Z
                                                                               
  16               Follicular adenoma                     C       N     F      Z
                                                                               
  17               Multinodular goiter                    N/C     N/C   F      Z
                                                                               
  18               Multinodular goiter                    N/C     N/C   F      F
                                                                               
  19               Papillary cancer & Hashimoto           C       C     F      Z

C = cytoplasmic; N = nuclear; F = focal; Z = zonal; ND = not determined; neg. = negative

Biopsy tissues used for immunohistochemical analyses were obtained from normal tissue adjacent to diseased areas. Samples were immediately frozen in liquid Nitrogen and stored at -80°C. On the day of analysis, tissue samples were gradually set to the temperature of -30°C for cryostat procedure. Seven sections were cut from each sample. The immunoperoxidase method was applied with Vector reagents utilizing the following primary antibodies: *a)*the anti-p53 polyclonal antibody CM-1 (Novocastra Laboratories Ltd) dilution 1:1000, *b)*the anti-STAT3 polyclonal antibody C-20 sc-482 clone (Santa Cruz Biotechnology) dilution 1:1000, *c)*the anti-CK19 monoclonal antibody b170 (Novocastra Laboratories Ltd) dilution 1:100, *d)*the anti-gp130 polyclonal antibody H-255 (Santa Cruz Biotechnology) dilution 1:250. The staining pattern was evaluated in epithelial cells both in terms of percentage of stained cells and staining intensity. In terms of percentage of stained cells, samples were classified as diffuse, zonal, focal and negative when the % of positive cells was \>50%, between 10-50%, \<10% and 0%, respectively. In terms of staining intensity, samples were subdivided into three categories: 1 + (low), 2 + (intermediate) and 3 + (high).

Results
=======

The results of immunohistochemical analyses are shown in Table [1](#T1){ref-type="table"}. Except for case number 8 (multinodular goiter) that was negative for both STAT3 and p53 expression, and case number 14 (papillary carcinoma) which was negative for STAT3, a diffuse pattern with an intermediate intensity in both nuclear and/or cytoplasmic localizations was observed in all the samples analyzed. An exclusive cytoplasmic localization of STAT3 was seen in 7 cases while a nuclear/cytoplasmic staining was detected in 10 cases. As for p53, three cases displayed an exclusive nuclear staining, 8 cases showed an exclusive cytoplasmic localization, 7 cases showed a nuclear/cytoplasmic positivity \[Figure [1](#F1){ref-type="fig"}\] and one case displayed no staining. gp130 staining was negative in two cases (3 and 8) while a zonal or focal membrane and cytoplasmic staining distribution of intermediate intensity (2+) was observed in most of the cases \[Figure [2](#F2){ref-type="fig"}\]. Cases 7, 15 and 19 showed an intense (3+) staining. Cytokeratin 19 (CK19) could not be determined in case 3, while 7 samples were negative, 8 showed a focal and 3 a zonal cytoplasmic distribution of intermediate intensity (2+).
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Discussion
==========

The present work addresses the usefulness of total thyroidectomy based on biomarkers expression in apparently normal thyroid tissue in patients with various thyroid diseases. We evaluated gp130 expression as a constituent of receptor complexes common to a number of cytokines implicated in inflammatory and immune responses. Of these, Interleukin-6 (IL-6), a most important pleiotropic cytokine, plays a central role in immune regulation, inflammation, hematopoiesis, and oncogenesis. In our series, gp 130 expression was detected in all patients with a scattered distribution represented by groups of cells of variable size, confirming the involvement of cytokines signalling through the gp130 subunit. An earlier immunohistochemical study on the expression pattern of the IL-6 family members and their receptor subunits in normal prostate, benign prostatic hyperplasia, and prostatic carcinoma has suggested a role for this cytokine in both paracrine and autocrine regulation of proliferative processes \[[@B10]\]. In another study on oesophageal carcinoma it has been suggested that IL-6 may contribute to cancer progression in an autocrine or paracrine manner acting as an antiapoptotic factor \[[@B6]\]. As for STAT3 and p53 expression, both markers were found to be overexpressed in 17 out of the 19 patients studied with a prevailing cytoplasmic localization (in 5 cases we observed an exclusively cytoplasmic pattern). Although our series was relatively small and no robust statistical analysis could be performed, the data obtained did not show any significant differential pattern of distribution amongst tissues obtained from multinodular goiter, adenoma, autoimmune disease or papillary carcinoma. As previously mentioned, the transcription factor STAT3 is most important for the signal transduction of interleukin-6 and related cytokines. Upon stimulation cytoplasmic STAT3 is phosphorylated and translocates to the nucleus. When constitutively activated, STAT3 plays an important role in tumorigenesis, as shown in human breast cancer \[[@B5]\]. Wild-type p53 contributes to negatively regulate STAT3 phosphorylation. Thus, a mutant p53, as is the case for cytoplasmic p53, is also associated with constitutive STAT3 activation \[[@B7]\]. In the present study we did not investigate the STAT3 phosphorylation and the p53 mutational status as our aim was to evaluate their subcellular localization in apparently normal thyroid tissue and to verify whether differences exist amongst different thyroid diseases. The results are suggestive of an ongoing modulation mechanism, where an increased p53 expression level is observed with a main cytoplasmic localization, going along with an almost equivalent localization pattern for STAT3.

Conclusion
==========

On the basis of the present data, it may be concluded that activation of STA3 signalling is a frequent event in thyroid diseases, being observed in normal thyroid tissue adjacent to different types of thyroid diseases. Such a process seems to involve the whole thyroid gland. Since a constitutively active STAT3, associated to cytoplasmic accumulation of p53, has been reported to represent a risk factor for tumor development \[[@B11]\], total thyroidectomy may be supported as an adequate therapeutic choice in cases where such alterations are detected.
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